Drug Profile
REP 2055
Alternative Names: REP 9ACLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator REPLICor; University of Adelaide
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 24 Jul 2023 Discontinued - Phase-I/II for Hepatitis B in Bangladesh (IV)
- 24 Jul 2023 Discontinued - Preclinical for Hepatitis B in Canada (SC)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Hepatitis-B in Canada (SC)